HKEX: 2157 - Lepu Biopharma Co., Ltd.

Yield per half year: -25.5%
Sector: Healthcare

Company Analysis Lepu Biopharma Co., Ltd.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (3.1 HK$) is less than fair price (3.31 HK$)
  • The stock's return over the last year (-15.34%) is higher than the sector average (-28.09%).

Disadvantages

  • Dividends (0%) are below the sector average (5.54%).
  • Current debt level 29% has increased over 5 years from 0%.
  • The company's current efficiency (ROE=-2.2%) is lower than the sector average (ROE=5.19%)

Similar companies

BeiGene, Ltd.

Zai Lab Limited

Alibaba Health Information Technology Limited

JD Health International Inc.

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Lepu Biopharma Co., Ltd. Healthcare Index
7 days 16% -4% 0.4%
90 days -3.9% -9.3% 9%
1 year -15.3% -28.1% 19.7%

2157 vs Sector: Lepu Biopharma Co., Ltd. has outperformed the "Healthcare" sector by 12.75% over the past year.

2157 vs Market: Lepu Biopharma Co., Ltd. has significantly underperformed the market by -35.02% over the past year.

Stable price: 2157 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.

Long period: 2157 with weekly volatility of -0.295% over the past year.

3. Summary of the report

3.1. General

P/E: 0
P/S: 25.92

3.2. Revenue

EPS -0.0121
ROE -2.2%
ROA -0.8055%
ROIC 0%
Ebitda margin -3830.77%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (3.1 HK$) is lower than the fair price (3.31 HK$).

Price not significantly lower than the fair price: The current price (3.1 HK$) is slightly lower than the fair price by 6.8%.

4.2. P/E

P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (35.42).

P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (26.67).

4.3. P/BV

P/BV vs Sector: The company's P/BV (5.98) is higher than that of the sector as a whole (3.68).

P/BV vs Market: The company's P/BV (5.98) is higher than that of the market as a whole (-11.94).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (25.92) is higher than that of the sector as a whole (7.59).

P/S vs Market: The company's P/S indicator (25.92) is higher than that of the market as a whole (2.77).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-15.37) is lower than that of the sector as a whole (2.91).

EV/Ebitda vs Market: The company's EV/Ebitda (-15.37) is lower than that of the market as a whole (9.94).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Negative and has fallen by -19.11% over the last 5 years.

Accelerating profitability: The return for the last year (-9.5%) exceeds the average return for 5 years (-19.11%).

Profitability vs Sector: The return for the last year (-9.5%) is lower than the return for the sector (-0.8813%).

5.4. ROE

ROE vs Sector: The company's ROE (-2.2%) is lower than that of the sector as a whole (5.19%).

ROE vs Market: The company's ROE (-2.2%) is lower than that of the market as a whole (6.3%).

5.5. ROA

ROA vs Sector: The company's ROA (-0.8055%) is lower than that of the sector as a whole (3.47%).

ROA vs Market: The company's ROA (-0.8055%) is lower than that of the market as a whole (3.39%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).

ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).

6. Finance

6.1. Assets and debt

Debt level: (29%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 0% to 29%.

Excess of debt: The debt is not covered by net income, percentage -3451.5%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '5.54%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Lepu Biopharma Co., Ltd.

9.3. Comments